The Fragmentation of Innovation: Why Niche Markets Matter This SummerGlobal Report·6 hours agoSTDN-5.47%CAPR-0.66%
Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR)Market Beat·22 hours agoCAPR-0.66%
The 2026 Biotech Divide: When Generative Biology Meets the FDA WallGlobal Report·1 day ago, 04:13 AMINM-7.57%TXG-3.72%
9 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·Jul 9 at 12:35 PMCAPR-0.66%LLY+0.86%
Capricor CFO Anthony Bergmann disposes of USD 732,158 in common sharesPUBT·Jun 29 at 08:30 PMCAPR-0.66%
Capricor Therapeutics (CAPR) Is Down 6.8% After Positive Five-Year HOPE-2 DMD Data And FDA UpdateSimplywall·Jun 27 at 06:56 PMCAPR-0.66%
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy | CAPR Stock NewsStockTitan·Jun 26 at 01:02 AMCAPR-0.66%
What's Going On With Capricor Therapeutics Stock On Friday?benzinga_article·Jun 26 at 01:06 PMCAPR-0.66%
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapybusinessinsider·Jun 26 at 09:15 AMCAPR-0.66%
Capricor says deramiocel meets primary endpoint in HOPE-3 Phase 3 Duchenne muscular dystrophy trialPUBT·Jun 26 at 08:05 AMCAPR-0.66%
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference | CAPR Stock NewsStockTitan·Jun 26 at 12:05 AMCAPR-0.66%
